Research programme: CNS disorder therapeutics - BioFocus DPI/Ono Pharmaceuticals
Latest Information Update: 16 Jul 2016
At a glance
- Originator BioFocus DPI
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in CNS-disorders in United Kingdom
- 31 Mar 2014 BioFocus DPI has been acquired by Charles River Laboratories
- 02 Sep 2012 Early research in CNS disorders in United Kingdom (unspecified route)